Latest news with #Blood
Yahoo
29-05-2025
- General
- Yahoo
Gang member who 'trafficked in fear, intimidation, and death' sentenced to life in prison
Gang member who 'trafficked in fear, intimidation, and death' sentenced to life in prison originally appeared on Bring Me The News. A Richfield man serving a 36 years in prison for murder has been sentenced to life behind bars for his role in the Bloods gang in the Twin Cities. The FBI said Desean Solomon "chose violence as a way of life — trafficking in fear, intimidation, and death to exert power, feed criminal ambition and expand the Blood's grip on the streets." He was targeted as part of an effort launched by the U.S. Attorney's Office in Minnesota to target gang members in the Twin Cities for RICO (racketeer influenced corrupt organization) offenses following a wave of crime between 2020 and 2022, and was the first to be sentenced in the crackdown. Solomon was already serving a sentence for killing a man at a north Minneapolis nightclub in June 2020, but the Star Tribune reports he was eligible for supervised release in 2047. Now he will spend the rest of his life behind bars after being handed a life sentence plus 20 years. A trial heard that the 34-year-old Solomon, aka "Black," has been a member of the Minneapolis Bloods street gang since at least 2020, and "has been a career criminal throughout his adulthood." His crimes include "two premeditated murders within a two-year span." The 2020 killing saw him and other Bloods members attack a rival gang member in the men's bathroom, with gunfire then breaking out outside the club. Solomon and another Bloods member fired several times, killing the victim. In April 2022, Solomon and other Bloods went to an Uptown bar and "started a large fight" with a rival gang, killing one of its members. While sentencing Solomon, Judge Susan R. Nelson said she was "searching for a kernel of hope that you could be trusted to not be a danger to society," but found he had "utter and complete disregard for human life" and a lack of remorse. "I am left with the certainty that you will always be a threat to public safety," she said. This story was originally reported by Bring Me The News on May 29, 2025, where it first appeared.
Yahoo
27-05-2025
- Business
- Yahoo
Covalon Announces Exciting New Clinical Research Evaluating VALGuard® Vascular Access Line Guard
Study results have been selected for presentation at two prestigious scientific meetings and are advancing to publication MISSISSAUGA, Ontario, May 27, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that exciting results from a clinical study evaluating the use of its VALGuard® Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard® across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). "Blood streams infections are a serious, but largely preventable complication that tragically affect hundreds of thousands of patients each year, with a mortality rate estimated at 15% to 20%," said Dr. Kate Evely, Vice President of Clinical Affairs for Covalon. "Major hospitals all over the United States are adding VALGuard® as an important part of their infection prevention program's toolkit to protect intravenous lines from gross contamination, a known source of infection. The study results provide impactful real-world evidence on the use of VALGuard®. The forthcoming publication of this investigator-initiated study is a testament to the dedication of the research team and our shared goal of advancing patient care." As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall – September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world. About VALGuardVALGuard® is a unique innovative transparent line guard designed to protect IV line connections and hubs from external contaminants, including body fluids, and secretions that can lead to serious, life-threatening blood stream infections. Those interested in learning about Covalon's solutions may visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About CovalonCovalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. View source version on Contacts To learn more about Covalon:Investor Relations, Covalon Technologies investors@ Website:
Business Wire
27-05-2025
- Health
- Business Wire
Covalon Announces Exciting New Clinical Research Evaluating VALGuard ® Vascular Access Line Guard
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that exciting results from a clinical study evaluating the use of its VALGuard ® Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard ® across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). 'Blood streams infections are a serious, but largely preventable complication that tragically affect hundreds of thousands of patients each year, with a mortality rate estimated at 15% to 20%,' said Dr. Kate Evely, Vice President of Clinical Affairs for Covalon. 'Major hospitals all over the United States are adding VALGuard ® as an important part of their infection prevention program's toolkit to protect intravenous lines from gross contamination, a known source of infection. The study results provide impactful real-world evidence on the use of VALGuard ®. The forthcoming publication of this investigator-initiated study is a testament to the dedication of the research team and our shared goal of advancing patient care.' As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall – September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world. About VALGuard VALGuard ® is a unique innovative transparent line guard designed to protect IV line connections and hubs from external contaminants, including body fluids, and secretions that can lead to serious, life-threatening blood stream infections. Those interested in learning about Covalon's solutions may visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About Covalon Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
Daily Record
26-05-2025
- Health
- Daily Record
Renfrewshire blood cancer patient taking on a coast-to-coast cycling challenge for charity
When Robert Howat told his wife Suzanne he planned to cycle 250 miles across Scotland just months after being diagnosed with blood cancer, she thought he was 'nuts'. A Renfrewshire blood cancer patient is set to take on a coast-to-coast cycling challenge for charity. This June, Robert Howat and two friends will set off on a coast-to-coast cycling challenge from Stranraer in Wigtownshire to Eyemouth, Berwickshire, all to raise money and awareness for Blood Cancer UK. And when the 50-year-old told his wife Suzanne he planned to cycle 250 miles across Scotland just months after being diagnosed with blood cancer, she thought he was 'nuts'. Robert, from Kilbarchan, was diagnosed with a form of blood cancer, chronic lymphocytic leukaemia (CLL) in 2024. 'I was quite fatigued, quite a lot of the time, me being me, I didn't tell anybody I wasn't feeling great,' Robert explained. 'I didn't want to feel embarrassed; I'd fall asleep sitting on the couch, I was dizzy all the time, and out of breath. My wife is a nurse practitioner, she took my stats, she didn't understand how I was still standing!' CLL is a slow-growing type of blood cancer that affects white blood cells and can often go unnoticed until it reaches a more advanced stage. Diagnosed while on oxygen in the hospital after a week, Robert admits his blood cancer diagnosis has been a shock for the family. He said: 'It's been a shock for the family, but I'm still trying to process why it's happened. I did everything right, I'm fit and healthy, I don't smoke, yet I've been dealt this hand.' Despite the shock, Robert's response is to carry on and be optimistic. He explained: 'When I got the diagnosis, I thought, 'What can I do to show people you can still live fully and help others while you're at it?' I'm on watch and wait, so I go in for check-ups every few months, and I want to show people what you can do with a blood cancer.' As a former police officer now working at Glasgow Airport, Robert is to take on an endurance challenge that would test even the fittest riders. Yet Robert's diagnosis of a blood cancer does mean that he's not able to train as much as he'd like. 'I have to be careful, CLL affects your immune system, so I need to avoid infection and balance exercise with recovery. I can't train like I used to,' he said. The 250-mile ride will take place over two days and include hills, wind, rain, and midges but Robert is looking forward to it. Setting off from Stranraer, the first day will take them to Newcastleton before the final leg to Eyemouth the next day. He's not doing it alone – he'll be joined by friends and fellow cyclists and supported by family and friends. His wife, Suzanne, despite calling the challenge 'mad', will be cheering from the sidelines, along with their daughters Eve and Adeline. Robert added: 'When I was well in the past I've run marathons, done tough mudders, and long bike rides but this is different. This one means more. I'm doing it show people you can still live with a cancer diagnosis.' The fundraising campaign has already began with over £1,000 coming into his JustGiving page. You can donate online by visiting Speaking about the challenge, Mairead Macleod, Blood Cancer UK's Scotland fundraising manager, said: 'Having a chronic leukaemia, a blood cancer, can be hard enough to navigate, and it's incredible Robert is still able to push himself to raise awareness and funds for Blood Cancer UK. 'Blood cancer is the UK's fifth most common blood cancer. It's because of the determination of people like Robert, we are able to fund more research into the prevention, diagnosis, and treatment of blood cancers. 'He's pedalling us closer to the day where we beat blood cancer for good.'
Yahoo
20-05-2025
- Sport
- Yahoo
Fundraiser organised in memory of Nicky Cunningham, a 'true warrior with the heart of a lion'
A fundraiser has been set up in memory of Muay Thai fighter, Nicky Cunningham. Members of Blood, Sweat and Tears Boxing Club and Evolve Muay Thai and the wider Newry community were left saddened by news of Nicky's sudden passing on Sunday 18 May. Nicky's former coach, Shane McIlroy has organised the GoFundMe page for his family. McIlroy paid his own personal tribute to Nicky as he described him as "a true warrior". READ MORE: Tom McKibbin prize money after he finishes tied 50th at the PGA Championship READ MORE: Rory McIlroy rejected by Phil Mickelson as statement made after PGA Championship Shane said: "I was Nicky's Muay Thai coach. He trained, he fought, he won, true warrior with the heart of a lion. [He] always had his demons but the ring was where he let it out. "Muay Thai was his true love it's what kept him going, he always needed a goal to strive for. He was a champion, my champion. Unfortunately Nicky lost his fight. "Life is such a cruel thing and if we lighten the load for his parents to bear at this tragic time by raising some funds and highlighting the need for mental health awareness, maybe Nicky's life will not have been in vain. Rest easy brother." So far, over £3,000 has been raised and if you would like to make a donation you can do so here. A funeral notice said Nicky was the 'dearly beloved son of Tom and Teresa, and much-loved brother of Stephen and the late Darren RIP.' The funeral notice added: 'Nicky will be sadly missed and lovingly remembered by his mother, father, brother and sister-in-law Kirsty, aunts, uncles, cousins and entire family circle and friends. Sacred Heart of Jesus, have mercy on his soul. Family flowers only. Donations in place of flowers to P.I.P.S.' The funeral will leave his home on Thursday, May 22 at 10.15am for 11 am Requiem Mass in the Church of St. Mary, Chapel Street, Newry. Interment afterwards in Monks Hill Cemetery. House private the morning of the funeral. Sign up to our free sports newsletter to get the latest headlines to your inbox
